Described herein are compositions, including an oral dosage regimen, for the treatment of NMDAR-related neuropsychiatric disorders such as depression and obsessive-compulsive disorder and that includes an NMDAR antagonist, such as D-cycloserine formulated to produce plasma levels in excess of 25 microgram/mL, combined with more recently developed antidepressants.L'invention concerne des compositions pour réduire les symptômes d'un trouble de stress post-traumatique. Les compositions comprennent une combinaison d'un antagoniste du récepteur de N-méthyl-D-aspartate (NMDA) et d'un agent anti-dépresseur.
